AzTrials
AzTrials

Pulmonary FibrosisPhase 3NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

A Phase 3 study testing BMS-986278 in people with Pulmonary Fibrosis, run by Bristol-Myers Squibb at 275 sites in 27 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)). Read more about this study

Who is it for?
Any age
Conditions the study is for
Pulmonary Fibrosis
What is being tested?
BMS-986278
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,380 participants
Where
275 sitesin 27 countries
Study dates
16 Dec 2026to 30 Mar 2030
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.

Who cannot join

  • Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation.
  • Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015.
  • Exhibit symptoms of heart failure at rest.
  • History of lung reduction surgery or lung transplant.
  • Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

275 sites in 27 countries. Contact the study team or a site near you to ask about taking part.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #. contact

275 sites in 27 countries

China40 sites

  • Local Institution - 0555

    Beijing, Beijing Municipality, 100020

    Site 0555

  • Local Institution - 0558

    Beijing, Beijing Municipality, 100050

    Site 0558

  • Local Institution - 0538

    Beijing, Beijing Municipality, 100730

    Site 0538

  • Local Institution - 0549

    Changsha, Hunan, 410011

    Site 0549

  • Local Institution - 0541

    Chengdu, SC, 610041

    Site 0541

  • Local Institution - 0550

    Chengdu, Sichuan, 610015

    Site 0550

  • Local Institution - 0543

    Guangzhou, Guangdong, 510120

    Site 0543

  • Local Institution - 0553

    Guangzhou, Guangdong, 510515

    Site 0553

  • Local Institution - 0574

    Hangzhou, Zhejiang, 310009

    Site 0574

  • Local Institution - 0576

    Hangzhou, Zhejiang, 310016

    Site 0576

  • Local Institution - 0552

    Hangzhou, ZJ, 310006

    Site 0552

  • Local Institution - 0563

    Hefei, AH, 230022

    Site 0563

  • Local Institution - 0569

    Hefei, Anhui, 230031

    Site 0569

  • Local Institution - 0540

    Hohhot, 010010

    Site 0540

  • Local Institution - 0559

    Lanzhou, 730000

    Site 0559

  • Local Institution - 0542

    Nanjing, 210008

    Site 0542

  • Local Institution - 0571

    Ningbo, Zhejiang, 315010

    Site 0571

  • Local Institution - 0548

    Shandong, Shandong, 250012

    Site 0548

  • Local Institution - 0575

    Shanghai, Shanghai Municipality, 200032

    Site 0575

  • Local Institution - 0572

    Shanghai, Shanghai Municipality, 200233

  • Local Institution - 0566

    Shanghai, 200040

    Site 0566

  • Local Institution - 0562

    Shanghai, 200092

    Site 0562

  • Local Institution - 0565

    Shanghai, 200127

    Site 0565

  • Local Institution - 0546

    Shanghai Shi, 200030

    Site 0546

  • Local Institution - 0551

    Shenyang, Liaoning, 110001

    Site 0551

  • Local Institution - 0554

    Shenyang, Liaoning, 110044

    Site 0554

  • Local Institution - 0557

    Shenzhen, GD, 518116

    Site 0557

  • Local Institution - 0561

    Shenzhen Shi, Guangdong, 518020

    Site 0561

  • Local Institution - 0544

    Shijiazhuang, HE, 050051

    Site 0544

  • Local Institution - 0573

    Suzhou, Jiangsu, 215008

    Site 0573

  • Local Institution - 0547

    Tianjin, Tianjin Municipality, 300052

    Site 0547

  • Local Institution - 0577

    Tianjin, TJ, 300222

    Site 0577

  • Local Institution - 0556

    Wuhan, Hubei, 430002

    Site 0556

  • Local Institution - 0570

    Wuxi, Jiangsu, 214023

    Site 0570

  • Local Institution - 0564

    Xi'an, 710100

    Site 0564

  • Local Institution - 0545

    Xuzhou, 221002

    Site 0545

  • Local Institution - 0568

    Yichang Shi, HE, 443099

    Site 0568

  • Local Institution - 0560

    Yinchuan, 750004

    Site 0560

  • Local Institution - 0539

    Zhengzhou, Henan, 450000

    Site 0539

  • Local Institution - 0567

    Zhengzhou, Henan, 450052

    Site 0567

Other trials in China

Japan40 sites

  • Local Institution - 0502

    Bunkyo-ku, Tokyo, 113-8431

    Site 0502

  • Local Institution - 0503

    Bunkyo-ku, Tokyo, 113-8519

    Site 0503

  • Local Institution - 0504

    Bunkyo-Ku, Tokyo, 113-8603

    Site 0504

  • Local Institution - 0511

    Chiba, 260-8677

    Site 0511

  • Local Institution - 0530

    Chikushino-shi, Fukuoka, 818-8502

    Site 0530

  • Local Institution - 0536

    Eiheiji-cho, Yoshida-gun, Fukui, 910-1193

    Site 0536

  • Local Institution - 0528

    Fukuoka, Fukuoka, 810-8563

    Site 0528

  • Local Institution - 0529

    Fukuoka, 812-8582

    Site 0529

  • Local Institution - 0535

    Ginowan-Shi, Okinawa, 901-2214

    Site 0535

  • Local Institution - 0515

    Hamamatsu, Shizuoka, 431-3192

    Site 0515

  • Local Institution - 0524

    Himeji-Shi, Hyōgo, 670-8520

    Site 0524

  • Local Institution - 0526

    Hiroshima, Hiroshima, 734-8530

    Site 0526

  • Local Institution - 0531

    Iizuka-shi, Fukuoka, 820-8505

    Site 0531

  • Local Institution - 0525

    Izumo-shi, Shimane, 693-8501

    Site 0525

  • Local Institution - 0512

    Kamogawa-Shi, Chiba, 296-0041

    Site 0512

  • Local Institution - 0523

    Kobe, Hyōgo, 650-0047

    Site 0523

  • Local Institution - 0537

    Kōriyama, Fukushima, 963-0197

    Site 0537

  • Local Institution - 0534

    Kumamoto, 861-4193

    Site 0534

  • Local Institution - 0532

    Kurume-Shi, Fukuoka, 830-0011

    Site 0532

  • Local Institution - 0518

    Matsusaka-shi, Mie-ken, 515-8544

    Site 0518

  • Local Institution - 0501

    Minato-ku, Tokyo, 105-8471

    Site 0501

  • Local Institution - 0509

    Mitaka-shi, Tokyo, 181-8611

    Site 0509

  • Local Institution - 0533

    Nagasaki, 852-8501

    Site 0533

  • Local Institution - 0516

    Nagoya, Aichi-ken, 466-8560

    Site 0516

  • Local Institution - 0513

    Naka-gun, Ibaraki, 3191113

    Site 0513

  • Local Institution - 0505

    Ōta-ku, Tokyo, 143-8541

    Site 0505

  • Local Institution - 0520

    Sakai, Osaka, 590-0197

    Site 0520

  • Local Institution - 0521

    Sakai, Osaka, 591-8555

    Site 0521

  • Local Institution - 0498

    Sapporo, Hokai-do, 060-8543

    Site 0498

  • Local Institution - 0499

    Sapporo, Hokkaido, 060-8648

    Site 0499

  • Local Institution - 0517

    Seto-shi, Aichi-ken, 489-8642

    Site 0517

  • Local Institution - 0514

    Shimotsuke, Tochigi, 329-0498

    Site 0514

  • Local Institution - 0508

    Shinjyu-Ku, Tokyo, 162-8655

    Site 0508

  • Local Institution - 0507

    Shinjyuku-ku, 160-0023

    Site 0507

  • Local Institution - 0519

    Takatsuki, Osaka, 569-8686

    Site 0519

  • Local Institution - 0522

    Tenri-shi, Nara, 632-8552

    Site 0522

  • Local Institution - 0500

    Tokyo, 105-8470

    Site 0500

  • Local Institution - 0506

    Tokyo, 153-8515

    Site 0506

  • Local Institution - 0527

    Ube, Yamaguchi, 755-0241

    Site 0527

  • Local Institution - 0510

    Yokohama, Kanagawa, 2360051

    Site 0510

Other trials in Japan

Argentina16 sites

  • Local Institution - 0010

    Buenos Aires, C1056ABI

    Site 0010

  • Local Institution - 0004

    Buenos Aires, C1426ABP

    Site 0004

  • Local Institution - 0005

    CABA, Distrito Federal, C1425FVH

    Site 0005

  • Local Institution - 0016

    CABA, 4190

    Site 0016

  • Local Institution - 0001

    Córdoba, Córdoba Province, X5003DCE

    Site 0001

  • Local Institution - 0013

    Florida, Vicente López, Buenos Aires, 1602

    Site 0013

  • Local Institution - 0002

    Godoy Cruz, Mendoza Province, 5501

    Site 0002

  • Local Institution - 0014

    Mar del Plata, Buenos Aires, 7600

    Site 0014

  • Local Institution - 0003

    Mar del Plata, B, 7600

    Site 0003

  • Local Institution - 0011

    Mendoza, M, 5500

    Site 0011

  • Local Institution - 0006

    Mendoza, 5500

    Site 0006

  • Local Institution - 0007

    Quilmes, Buenos Aires, 1878

  • Local Institution - 0015

    Rosario, S, 2000

    Site 0015

  • Local Institution - 0009

    San Juan Bautista, Buenos Aires, 1888

    Site 0009

  • Local Institution - 0012

    San Miguel de Tucumán, Tucumán Province, T4000JCU

    Site 0012

  • Local Institution - 0008

    Santa Fe, 3000

    Site 0008

Other trials in Argentina

India16 sites

  • Local Institution - 0264

    Ahemdabad, 380060

    Site 0264

  • Local Institution - 0271

    Bangalore, 560034

    Site 0271

  • Local Institution - 0269

    Belagavi, Karnataka, 590010

    Site 0269

  • Local Institution - 0260

    Dehradun, Uttarakhand, 248001

    Site 0260

  • Local Institution - 0272

    Delhi, 110029

    Site 0272

  • Local Institution - 0274

    Jaipur, 302039

    Site 0274

  • Local Institution - 0258

    Kolkata, West Bengal, 700014

    Site 0258

  • Local Institution - 0270

    Kolkata, West Bengal, 700027

    Site 0270

  • Local Institution - 0259

    Lucknow, 226006

    Site 0259

  • Local Institution - 0273

    Lucknow, 226021

    Site 0273

  • Local Institution - 0263

    Nagpur, Maharashtra, 044009

    Site 0263

  • Local Institution - 0275

    Nagpur, 440010

    Site 0275

  • Local Institution - 0268

    New Delhi, National Capital Territory of Delhi, 110 030

    Site 0268

  • Local Institution - 0261

    Pune, Maharashtra, 411001

    Site 0261

  • Local Institution - 0266

    Pune, Maharashtra, 411001

    Site 0266

  • Local Institution - 0265

    Pune, Maharashtra, 411004

    Site 0265

Other trials in India

South Korea15 sites

  • Local Institution - 0208

    Bucheon-si, 14584

    Site 0208

  • Local Institution - 0207

    Bucheon-si, 420-717

    Site 0207

  • Local Institution - 0197

    Busan, Pusan-Kwangyǒkshi, 0

    Site 0197

  • Local Institution - 0198

    Busan, 612-030

    Site 0198

  • Local Institution - 0196

    Goyang, 411-706

  • Local Institution - 0206

    Goyang-si, Gyeonggi-do, 10475

    Site 0206

  • Local Institution - 0204

    Iksan, 570-711

    Site 0204

  • Local Institution - 0209

    Kyunggi-do, 463-707

    Site 0209

  • Local Institution - 0205

    Namdong-gu, Incheon-gwangyeoksi [Incheon], 21565

    Site 0205

  • Local Institution - 0200

    Seoul, Seoul-teukbyeolsi, 05505

    Site 0200

  • Local Institution - 0199

    Seoul, 03080

    Site 0199

  • Local Institution - 0202

    Seoul, 120-752

    Site 0202

  • Local Institution - 0195

    Seoul, 140-887

    Site 0195

  • Local Institution - 0201

    Suwon, 16499

    Site 0201

  • Local Institution - 0203

    Ulsan, Dong-gu, 682-714

    Site 0203

Other trials in South Korea

Brazil13 sites

  • Local Institution - 0194

    Barra Mansa, Rio de Janeiro, 27323-240

    Site 0194

  • Local Institution - 0086

    Belo Horizonte, Minas Gerais, 30130-100

    Site 0086

  • Local Institution - 0031

    Belo Horizonte, Minas Gerais, 30430-142

  • Local Institution - 0030

    Blumenau, Santa Catarina, 89030-100

    Site 0030

  • Local Institution - 0033

    Botucatu, São Paulo, 18618-687

  • Local Institution - 0027

    Porto Alegre, Rio Grande do Sul, 90160-092

    Site 0027

  • Local Institution - 0028

    Porto Alegre, Rio Grande do Sul, 9050-170

    Site 0028

  • Local Institution - 0032

    Porto Alegre, Rio Grande do Sul, 90610-000

    Site 0032

  • Local Institution - 0193

    Rio de Janeiro, 20551-030

    Site 0193

  • Local Institution - 0026

    Santo André, São Paulo, 09060-870

    Site 0026

  • Local Institution - 0025

    Santo André, 09190-510

    Site 0025

  • Local Institution - 0066

    São Paulo, 01323-020

    Site 0066

  • Local Institution - 0192

    São Paulo, 04023-062

    Site 0192

Other trials in Brazil

Mexico13 sites

  • Local Institution - 0019

    Aguascalientes, Aguascalientes, 20116

  • Local Institution - 0037

    Chihuahua City, Chihuahua, 31203

    Site 0037

  • Local Institution - 0035

    Col Garcia Binersa, Yucatán, 97070

    Site 0035

  • Local Institution - 0022

    Guadalajara, Jalisco, 44160

    Site 0022

  • Local Institution - 0021

    Guadalajara, Jalisco, 44340

    Site 0021

  • Local Institution - 0018

    Guadalajara, 44130

    Site 0018

  • Local Institution - 0034

    Mérida, Yucatán, 97125

    Site 0034

  • Local Institution - 0023

    Metepec, Edo de Mexico, 52170

    Site 0023

  • Local Institution - 0036

    México, DIF, 14050

    Site 0036

  • Local Institution - 0038

    Monterrey, Nuevo León, 64460

  • Local Institution - 0024

    Morelia, Michoacán, 58260

    Site 0024

  • Local Institution - 0017

    Oaxaca City, Oaxaca, 68000

    Site 0017

  • Local Institution - 0020

    Oaxaca City, Oaxaca, 68020

Other trials in Mexico

Spain13 sites

  • Local Institution - 0069

    Barcelona, 08036

    Site 0069

  • Local Institution - 0074

    Barcelona, 08907

  • Local Institution - 0075

    Barcelona, 8035

    Site 0075

  • Local Institution - 0071

    Coslada, 28822

    Site 0071

  • Local Institution - 0073

    Girona, 17001

    Site 0073

  • Local Institution - 0068

    Madrid, 28006

    Site 0068

  • Local Institution - 0067

    Madrid, 28040

    Site 0067

  • Local Institution - 0084

    Madrid, 28040

    Site 0084

  • Local Institution - 0072

    Madrid, 28046

    Site 0072

  • Local Institution - 0076

    Málaga, 29010

  • Local Institution - 0070

    Oviedo, 33006

    Site 0070

  • Local Institution - 0083

    Santander, Cantabria, 39008

    Site 0083

  • Local Institution - 0085

    Santiago de Compostela, C, 15706

    Site 0085

Other trials in Spain

France12 sites

  • Local Institution - 0236

    Angers, Maine-et-Loire, 49933

    Site 0236

  • Local Institution - 0242

    Bobigny, 93009

    Site 0242

  • Local Institution - 0238

    Brest, 29609

    Site 0238

  • Local Institution - 0244

    Dijon, 21000

    Site 0244

  • Local Institution - 0245

    Grenoble, Auvergne-Rhône-Alpes, 38043

    Site 0245

  • Local Institution - 0243

    Marseille, Provence-Alpes-Côte d'Azur Region, 13015

    Site 0243

  • Local Institution - 0246

    Nantes, Pays de la Loire Region, 44093

    Site 0246

  • Local Institution - 0240

    Nice, 06000

    Site 0240

  • Local Institution - 0239

    Paris, 75018

    Site 0239

  • Local Institution - 0241

    Pessac, 33604

    Site 0241

  • Local Institution - 0247

    Saint-Genis-Laval, 69563

    Site 0247

  • Local Institution - 0237

    Toulouse, 31059

Other trials in France

Canada11 sites

  • Local Institution - 0167

    Burlington, Ontario, L7N 3V2

    Site 0167

  • Local Institution - 0171

    Greenfield Park, Quebec, J4V 2H1

  • Local Institution - 0170

    Hamilton, Ontario, L8N 4A6

    Site 0170

  • Local Institution - 0172

    Montreal, Quebec, H2X 1R9

    Site 0172

  • Local Institution - 0163

    Owen Sound, Ontario, N4K 6M9

    Site 0163

  • Local Institution - 0166

    Sherwood Park, Alberta, T8H 0N2

    Site 0166

  • Local Institution - 0169

    Toronto, Ontario, M5T 3A9

    Site 0169

  • Local Institution - 0164

    Trois-Rivières, Quebec, G8T 7A1

    Site 0164

  • Local Institution - 0173

    Trois-Rivières, Quebec, G9S4P3

  • Local Institution - 0165

    Vancouver, British Columbia, V5Z 1M9

    Site 0165

  • Local Institution - 0168

    Vancouver, British Columbia, V6Z 1Y6

    Site 0168

Other trials in Canada

Australia10 sites

  • Local Institution - 0289

    Adelaide, South Australia, 5000

    Site 0289

  • Local Institution - 0287

    Camperdown, New South Wales, 2050

    Site 0287

  • Local Institution - 0290

    Chermside, Queensland, 4032

    Site 0290

  • Local Institution - 0288

    Frankston, Victoria, 3199

  • Local Institution - 0291

    Greenslopes, Queensland, 4120

    Site 0291

  • Local Institution - 0286

    Melbourne, 3128

    Site 0286

  • Local Institution - 0285

    Murdoch, Western Australia, 6150

    Site 0285

  • Local Institution - 0292

    Nedlands, Western Australia, 6009

    Site 0292

  • Local Institution - 0293

    South Brisbane, Queensland, 4101

    Site 0293

  • Local Institution - 0284

    Wentworthville, NSW2145

    Site 0284

Other trials in Australia

Colombia10 sites

  • Local Institution - 0043

    Bogotá, DC, 110111

    Site 0043

  • Local Institution - 0046

    Bogotá, DC, 110131

    Site 0046

  • Local Institution - 0039

    Bogotá, 0

    Site 0039

  • Local Institution - 0048

    Bogotá

    Site 0048

  • Local Institution - 0041

    Floridablanca, Santander Department, 681004

    Site 0041

  • Local Institution - 0042

    Manizales, 0

  • Local Institution - 0044

    Medellín, ANT, 050021

    Site 0044

  • Local Institution - 0047

    Medellín, ANT, 050034

  • Local Institution - 0040

    Santiago de Cali, VAC, 760046

    Site 0040

  • Local Institution - 0045

    Zipaquirá, 250252

    Site 0045

Other trials in Colombia

United Kingdom9 sites

  • Local Institution - 0316

    Birmingham, BIR, B9 5SS

    Site 0316

  • Local Institution - 0319

    Birmingham, B15 2WB

    Site 0319

  • Local Institution - 0317

    Cambridge, Cambridgeshire, CB2 0AY

    Site 0317

  • Local Institution - 0497

    Cottingham, Yorkshire and the Humber, HU16 5JQ

    Site 0497

  • Local Institution - 0312

    Edinburgh, EDH, EH16 4SA

    Site 0312

  • Local Institution - 0496

    Leeds, Yorkshire, LS9 7TF

    Site 0496

  • Local Institution - 0315

    London, Greater London, SW3 6NP

    Site 0315

  • Local Institution - 0318

    Oxford, OX3 7LE

    Site 0318

  • Local Institution - 0314

    Peterborough, PTE, PE3 9GZ

    Site 0314

Other trials in United Kingdom

Chile8 sites

  • Local Institution - 0054

    Concepción, Biobio, 4030000

    Site 0054

  • Local Institution - 0052

    Curicó, Maule Region, 3340000

    Site 0052

  • Local Institution - 0050

    Quillota, Valparaiso, 2260000

    Site 0050

  • Local Institution - 0053

    Santiago, Santiago Metropolitan, 7620157

    Site 0053

  • Local Institution - 0055

    Santiago, Santiago Metropolitan, 7750495

    Site 0055

  • Local Institution - 0051

    Talca, Maule Region, 3466706

    Site 0051

  • Local Institution - 0029

    Talcahuano, BI, 4260000

    Site 0029

  • Local Institution - 0057

    Viña del Mar, Valparaiso, 2531172

    Site 0057

Other trials in Chile

Peru8 sites

  • Local Institution - 0063

    Lima, LIM, 15033

    Site 0063

  • Local Institution - 0058

    Lima, 15023

    Site 0058

  • Local Institution - 0061

    Lima, 15073

    Site 0061

  • Local Institution - 0064

    Lima, Lima 27

    Site 0064

  • Local Institution - 0060

    Lima, LIMA 31

    Site 0060

  • Local Institution - 0065

    Lima, Lima 41

    Site 0065

  • Local Institution - 0062

    Piura, 20001

    Site 0062

  • Local Institution - 0059

    San Miguel, LIM, 15088

    Site 0059

Other trials in Peru

Taiwan6 sites

  • Local Institution - 0323

    Kaohsiung City, 807

    Site 0323

  • Local Institution - 0321

    Kaohsiung City, 83301

    Site 0321

  • Local Institution - 0322

    Taichung, 404332

    Site 0322

  • Local Institution - 0325

    Taichung, 407

    Site 0325

  • Local Institution - 0324

    Taipei, 100

    Site 0324

  • Local Institution - 0326

    Taipei, 112

    Site 0326

Other trials in Taiwan

Belgium5 sites

  • Local Institution - 0248

    Brussels, 1200

    Site 0248

  • Local Institution - 0251

    Kortrijk, 8500

    Site 0251

  • Local Institution - 0252

    Leuven, Vlaams-Brabant, 3000

    Site 0252

  • Local Institution - 0250

    Liège, 4000

    Site 0250

  • Local Institution - 0249

    Yvoir, Namur, 5530

    Site 0249

Other trials in Belgium

Netherlands5 sites

  • Local Institution - 0253

    Amsterdam, 1081 BT

    Site 0253

  • Local Institution - 0257

    Heerlen, 6419 PC

    Site 0257

  • Local Institution - 0254

    Leiden, 2300 RC

    Site 0254

  • Local Institution - 0255

    Nieuwegein, 3425 CM

    Site 0255

  • Local Institution - 0256

    Rotterdam, South Holland, 3061BC

    Site 0256

Other trials in Netherlands

Portugal5 sites

  • Local Institution - 0077

    Lisbon, 1769-001

    Site 0077

  • Local Institution - 0078

    Loures, 2674-514

    Site 0078

  • Local Institution - 0079

    Porto, 4099-001

    Site 0079

  • Local Institution - 0082

    Porto, 4200-319

    Site 0082

  • Local Institution - 0081

    Vila Nova de Gaia, Porto District, 4434-502

    Site 0081

Other trials in Portugal

Denmark4 sites

  • Local Institution - 0488

    Aarhus, Region Midt, 8200

  • Local Institution - 0489

    Copenhagen, 2100

    Site 0489

  • Local Institution - 0487

    Hellerup, Capital Region, 2900

    Site 0487

  • Local Institution - 0486

    Odense C, Region Syddanmark, 5000

    Site 0486

Other trials in Denmark

Ireland4 sites

  • Local Institution - 0493

    Drogheda, Louth, A92 VW28

  • Local Institution - 0494

    Dublin, 0

    Site 0494

  • Local Institution - 0492

    Dublin, D15 X40D

  • Local Institution - 0495

    Tallaght, Dublin, 0

    Site 0495

Other trials in Ireland

United States3 sites

  • Local Institution - 0113

    Birmingham, Alabama, 35294

    Site 0113

  • Local Institution - 0111

    Ocala, Florida, 34471

    Site 0111

  • Local Institution - 0119

    Philadelphia, Pennsylvania, 19140-5103

    Site 0119

Other trials in United States

Finland2 sites

  • Local Institution - 0490

    Helsinki, 00290

    Site 0490

  • Local Institution - 0491

    Turku, Laensi-Suomen Laeaeni, 20521

    Site 0491

Other trials in Finland

Germany2 sites

  • Local Institution - 0179

    Coswig, Saxony, 01640

    Site 0179

  • Local Institution - 0186

    Stralsund, Mecklenburg-Vorpommern, 18435

    Site 0186

Other trials in Germany

Greece2 sites

  • Local Institution - 0234

    Heraklion, 711 10

    Site 0234

  • Local Institution - 0229

    Ioannina, Ípeiros, 455 00

    Site 0229

Other trials in Greece

Italy2 sites

  • Local Institution - 0211

    Florence, Tuscany, 50134

    Site 0211

  • Local Institution - 0221

    Palermo, 90127

    Site 0221

Other trials in Italy

Israel1 site

  • Local Institution - 0279

    Petah Tikva, 4941492

    Site 0279

Other trials in Israel

About this study

Official title: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Being tested
BMS-986278
Keywords
LPA1 receptor antagonist, Idiopathic pulmonary fibrosis, Progressive pulmonary fibrosis, Long-term extension, IPF, PPF, IM027068, IM0271015, Follow up
Medical subject headings
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BMS-986278Drug

    Also called Admilparant

    Specified dose on specified days

Study groups in NCT07441408
Study groupRoleWhat they receive
BMS-986278 ArmExperimentalNot described
Receives: Drug: BMS-986278

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Measured: Up to Week 100

  2. Number of Participants With Serious Adverse Events (SAEs)

    Measured: Up to Week 100

  3. Number of Participants With AEs leading to Discontinuation

    Measured: Up to Week 100

  4. Number of Participants With AEs leading to Deaths

    Measured: Up to Week 100

  5. Number of Participants With Clinically Significant Laboraty Abnormalities

    Measured: Up to Week 100

  6. Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities

    Measured: Up to Week 100

  7. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Measured: Up to Week 100

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2026
  2. Study start16 Dec 2026 (estimated)
  3. Primary completion22 Nov 2029 (estimated)
  4. Study completion30 Mar 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
2,380 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07441408
Sponsor's protocol ID
IM027-1016
Other IDs
2025-522373-10, U1111-1322-7787, 2025
Status last verified
Aug 2026
First submitted
25 Feb 2026
Last updated
14 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing BMS-986278 in people with Pulmonary Fibrosis, run by Bristol-Myers Squibb at 275 sites in 27 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 275 sites in China, Japan, Argentina, India, South Korea and 22 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com (855-907-3286, Clinical.Trials@bms.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment Emergent Adverse Events (TEAEs) (time frame: Up to Week 100). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07441408.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in